Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

• ClinicalTrials.gov Identifier: NCT03274687
• Recruitment Status: Active, not recruiting
• First Posted: September 7, 2017
• Results First Posted: June 6, 2022
• Last Update Posted: June 28, 2022
• Sponsor: NRG Oncology
• Collaborator: National Cancer Institute (NCI)
• Information provided by (Responsible Party): NRG Oncology

Tracking Information

• First Submitted Date: September 5, 2017
• First Posted Date: September 7, 2017
• Results First Submitted Date: May 10, 2022
• Results First Posted Date: June 6, 2022
• Last Update Posted Date: June 28, 2022
• Actual Study Start Date: July 28, 2017
• Actual Primary Completion Date: December 1, 2020 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: May 10, 2022)

• Change in Urinary Domain of the Expanded Prostate Cancer Index (EPIC) at Two Years [ Time Frame: Baseline (randomization), 2 years ]
  The EPIC is a prostate cancer health-related quality of life (HRQOL) self-administered instrument measuring patient-reported urinary, bowel, sexual, and hormonal symptoms related to prostate cancer treatments. Response options for each item form a Likert scale with scores transformed linearly to a 0-100 scale. Domain scores are also on a 0-100 scale with higher scores representing better HRQOL. The urinary domain contains 12 items. Change from baseline is calculated by subtracting baseline from later score, with a positive change score indicating increased HRQOL.
• Change in Bowel Domain of the Expanded Prostate Cancer Index (EPIC) at Two Years [ Time Frame: Baseline, 2 years ]
  The EPIC is a prostate cancer health-related quality of life (HRQOL) self-administered instrument measuring patient-reported urinary, bowel, sexual, and hormonal symptoms related to prostate cancer treatments. Response options for each item form a Likert scale with scores transformed linearly to a 0-100 scale. Domain scores are also on a 0-100 scale with higher scores representing better HRQOL. The bowel domain contains 14 items. Change from baseline is calculated by subtracting baseline from later score, with a positive change score indicating increased HRQOL.

Original Primary Outcome Measures (submitted: September 5, 2017)

• Change in score for the GI domain of the EPIC [ Time Frame: Baseline to 2 years ]
  Will be analyzed using a t-test with a significance level of 0.025. If the data are determined to be non-normal, a Wilcoxon test may be used instead. Missing data will be assessed.
• Change in score for the total GU domain (combined urinary incontinence and urinary irritative/obstructive scales) of the EPIC [ Time Frame: Baseline to 2 years ]
  Will be analyzed using a t-test with a significance level of 0.025. If the data are determined to be non-normal, a Wilcoxon test may be used instead. Missing data will be assessed.

Current Secondary Outcome Measures (submitted: June 6, 2022)

• Change in Urinary Domain Score of the Expanded Prostate Cancer Index (EPIC) at End of Radiation Therapy (RT), 6 Months, 1 and 5 Years [ Time Frame: Baseline, end of RT, then 6 months,1 and 5 years from the start of RT (5 year time point has not yet been reached). RT dates depend on timing and duration of androgen deprivation therapy (ADT) (optional) and RT. ]
  The EPIC is a prostate cancer health-related quality of life (HRQOL) self-administered instrument measuring patient-reported urinary, bowel, sexual, and hormonal symptoms related to prostate cancer treatments. Response options for each item form a Likert scale with scores transformed linearly to a 0-100 scale. Domain scores are also on a 0-100 scale with higher scores representing better HRQOL. The urinary domain contains 12 items. Change from baseline is calculated by subtracting baseline from later score, with a positive change score indicating increased HRQOL.
• Change in Bowel Domain Score of the Expanded Prostate Cancer Index (EPIC) at End of RT, 6 Months, 1 and 5 Years [ Time Frame: Baseline, end of RT, then 6 months,1 and 5 years from the start of RT (5 year time point has not yet been reached). RT dates depend on timing and duration of ADT (optional) and RT. ]
  The EPIC is a prostate cancer health-related quality of life (HRQOL) self-administered instrument measuring patient-reported urinary, bowel, sexual, and hormonal symptoms related to prostate cancer treatments. Response options for each item form a Likert scale with scores transformed linearly to a 0-100 scale. Domain scores are also on a 0-100 scale with higher scores representing better HRQOL. The bowel domain contains 14 items. Change from baseline is calculated by subtracting baseline from later score, with a positive change score indicating increased HRQOL.
• Percentage of Participants With Biochemical Failure [ Time Frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 3.0 years. ]
  Biochemical failure was analyzed using two different definitions. The protocol definition of biochemical failure is a PSA measurement ≥ 0.4 ng/mL and rising (i.e. PSA ≥ 0.4 ng/mL followed by a value higher than the first by any amount) or followed by initiation of salvage hormones. The Phoenix definition of biochemical failure is a PSA measurement ≥ PSA nadir + 2 ng/mL where nadir is the lowest post-RT PSA value. Time to biochemical failure is defined as time from randomization to the date of first biochemical failure, last known follow-up (censored), or death without biochemical failure (competing risk). Biochemical failure rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year rates are provided.
• Percentage of Participants With Progression [ Time Frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 3.0 years. Two-year rates reported here. Follow-up schedule: end of RT, then 6, 12, 18, 24 months from start of RT, then yearly. ]
  Progression (failure) is defined as the first occurrence of biochemical failure, local failure, regional failure, distant failure, institution of new unplanned anticancer treatment, or death from prostate cancer. Time to progression is defined as time from randomization to the date of progression, last known follow-up (censored), or death without progression (competing risk). Progression rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year rates are provided.
• Percentage of Participants With Local-Regional Failure [ Time Frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 3.0 years. Two-year rates reported here. Follow-up schedule: end of RT, then 6, 12, 18, 24 months from start of RT, then yearly. ]
  Local-regional failure is defined as local or regional failure. Local failure is defined as the development of a new biopsy-proven mass in the prostate bed. Regional failure is defined as radiographic evidence (CT or MRI) of lymphadenopathy (lymph node size ≥ 1.0 cm in the short axis) in a patient without the diagnosis of a hematologic/lymphomatous disorder associated with adenopathy. Time to local-regional failure is defined as time from randomization to the date of first local-regional failure, last known follow-up (censored), or death without local-regional (competing risk). Local-regional failure rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year rates are provided.
• Percentage of Participants Receiving Salvage Therapy [ Time Frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 3.0 years. Two-year rates reported here. Follow-up schedule: end of RT, then 6, 12, 18, 24 months from start of RT, then yearly. ]
  Salvage therapy is defined as the initiation of new unplanned anticancer treatment. Time to salvage therapy initiation is defined as time from randomization to the date of first salvage therapy, last known follow-up (censored), or death without salvage therapy (competing risk). Salvage therapy rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of salvage initiation times be compared between the arms, which is reported in the statistical analysis results. Two-year rates are provided.
• Percentage of Participants With Distant Metastasis [ Time Frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 3.0 years. Two-year rates reported here. Follow-up schedule: end of RT, then 6, 12, 18, 24 months from start of RT, then yearly. ]
  Distant metastasis (failure) is defined as radiographic evidence of hematogenous spread evaluated by bone scan, CT, or MRI. Time to distant metastasis is defined as time from randomization to the date of first distant metastasis, last known follow-up (censored), or death without local recurrence (competing risk). Distant metastasis rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. Two-year rates are provided.
• Percentage of Participants Who Died From Prostate Cancer (Prostate Cancer Specific Mortality) [ Time Frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 3.0 years. Two-year rates reported here. Follow-up schedule: end of RT, then 6, 12, 18, 24 months from start of RT, then yearly. ]
  Cause of death was centrally reviewed. Count and percentage at time of analysis are reported.
• Percent of Participants Alive (Overall Survival) [ Time Frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 3.0 years. Two-year rates reported here. Follow-up schedule: end of RT, then 6, 12, 18, 24 months from start of RT, then yearly. ]
  Overall survival time is defined as time from registration/randomization to the date of death (failure) from any cause or last known follow-up (censored). Overall survival rates are estimated by the Kaplan-Meier method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. 2-year rates are provided.
• Number of Participants With Grade 3+ Adverse Events [ Time Frame: From randomization to last follow-up. Maximum follow-up at time of analysis was 3.0 years. Follow-up schedule: end of RT, then 6, 12, 18, 24 months from start of RT, then yearly. ]
  Common Terminology Criteria for Adverse Events (CTCAE) version 4 grades adverse event severity from 1=mild to 5=death. Summary data is provided in this outcome measure; see Adverse Events Module for specific adverse event data. Counts of participants with any grade 3 or higher adverse event, any grade 3 or higher gastrointestinal adverse events, and any grade 3 or higher genitourinary adverse events are reported. Adverse events of any attribution are included.

Original Secondary Outcome Measures (submitted: September 5, 2017)

• Distant Metastasis (DM) defined as radiographic evidence of hematogenous spread evaluated by bone scan, CT, or MRI [ Time Frame: From the date of randomization to the date of documented DM, assessed up to 5 years ]
  Will treat death as a competing risk and will be estimated by the cumulative incidence method. Fine and Gray's regression will be used. Adjusted HRs and the respective 95% confidence interval will be computed. Baseline PSA, stratification variables (baseline EPIC-26 score and ADT status), and, as appropriate, age, race, and other covariates (Gleason, T-stage), will be adjusted for in this analysis. Statistical power will be limited for these analyses.
• Freedom From Biochemical Failure (FFBF) where biochemical failure is defined as a PSA >= 0.4 ng/mL and rising. [ Time Frame: Up to 5 years ]
  Will be estimated by the Kaplan-Meier method.
• Incidence of adverse events (AEs) evaluated according to Common Terminology Criteria for Adverse Events version 4.0 [ Time Frame: Up to 5 years ]
  Counts of all AEs by grade will be provided by treatment arm. Counts and frequencies will be provided for the worst grade AE experienced by the patient by treatment arm. A Chi-square test will be used to compare the number of patients with at least 1 grade 3 or higher AE between the treatment arms. A comparison of grade 3 and higher GU and GI events related to treatment (separately) between treatment arms will also be tested using a Chi-square test.
• Local failure defined as the development of a new biopsy-proven mass in the prostate bed after enrollment in the protocol [ Time Frame: From the date of randomization to the date of documented local failure, assessed up to 5 years. ]
  Will treat death as a competing risk and will be estimated by the cumulative incidence method. Fine and Gray's regression will be used. Adjusted HRs and the respective 95% confidence interval will be computed. Baseline PSA, stratification variables (baseline EPIC-26 score and ADT status), and, as appropriate, age, race, and other covariates (Gleason, T-stage), will be adjusted for in this analysis. Statistical power will be limited for these analyses.
• Overall Survival Rates [ Time Frame: From date of randomization to death, assessed up to 5 years ]
  Will treat death as a competing risk and will be estimated by the cumulative incidence method. Cox regression will be used to obtain HRs. Will be estimated by the Kaplan-Meier method. Adjusted HRs and the respective 95% confidence interval will be computed. Baseline PSA, stratification variables (baseline EPIC-26 score and ADT status), and, as appropriate, age, race, and other covariates (Gleason, T-stage), will be adjusted for in this analysis. Statistical power will be limited for these analyses.
• Patient-reported GI symptoms assessed using the EPIC [ Time Frame: Up to 5 years ]
  The change scores will be analyzed using a t-test. If the data are determined to be non-normal, a Wilcoxon test may be used instead. A longitudinal analysis incorporating all follow-up time points will be conducted using a general linear model with maximum likelihood estimation, adjusting for baseline domain score, treatment arm, Gleason score, baseline PSA, T-stage, age, and race. If found to significantly differ between arms, then analysis of the function and bother subscales will be undertaken to assess which particular subscale is driving the significant difference.
• Patient-reported GU symptoms assessed using the EPIC [ Time Frame: Up to 5 years ]
  The change scores will be analyzed using a t-test. If the data are determined to be non-normal, a Wilcoxon test may be used instead. A longitudinal analysis incorporating all follow-up time points will be conducted using a general linear model with maximum likelihood estimation, adjusting for baseline domain score, treatment arm, Gleason score, baseline PSA, T-stage, age, and race. If found to significantly differ between arms, then analysis of the incontinency and irritative/obstructive subscales will be undertaken to assess which particular subscale is driving the significant difference.
• Prostate Cancer Specific Mortality (PCSM) [ Time Frame: From the date of randomization to the date of death due to prostate cancer, assessed up 5 years ]
  Will treat death as a competing risk and will be estimated by the cumulative incidence method. Fine and Gray's regression will be used. Adjusted HRs and the respective 95% confidence interval will be computed. Baseline PSA, stratification variables (baseline EPIC-26 score and ADT status), and, as appropriate, age, race, and other covariates (Gleason, T-stage), will be adjusted for in this analysis. Statistical power will be limited for these analyses.
• Regional failure defined as radiographic evidence of lymphadenopathy in a patient without the diagnosis of a hematologic/lymphomatous disorder associated with adenopathy evaluated by CT or MRI [ Time Frame: From the date of randomization to the date of documented regional metastasis, assessed up to 5 years ]
  Will treat death as a competing risk and will be estimated by the cumulative incidence method. Fine and Gray's regression will be used. Adjusted HRs and the respective 95% confidence interval will be computed. Baseline PSA, stratification variables (baseline EPIC-26 score and ADT status), and, as appropriate, age, race, and other covariates (Gleason, T-stage), will be adjusted for in this analysis. Statistical power will be limited for these analyses.
• Time To Progression (TTP) where progression is defined as the first occurrence of biochemical failure, local failure, regional failure, DM, institution of new unplanned anticancer treatment, or death from prostate cancer [ Time Frame: Up to 5 years ]
  Will treat death as a competing risk and will be estimated by the cumulative incidence method. Cox regression will be used to obtain hazard ratios (HRs). Fine and Gray's regression will be used. Adjusted HRs and the respective 95% confidence interval will be computed. Baseline PSA, stratification variables (baseline EPIC-26 score and ADT status), and, as appropriate, age, race, and other covariates (Gleason, T-stage), will be adjusted for in this analysis. Statistical power will be limited for these analyses.

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
• Official Title: A Randomized Phase III Trial of Hypofractionated Post-prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-prostatectomy Radiation Therapy (COPORT)
• Brief Summary: This randomized phase III trial studies how well hypofractionated radiation therapy works compared to conventional radiation therapy after surgery in treating patients with prostate cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Conventional radiation therapy uses high energy x-rays, gamma rays, neutrons, protons, or other sources to kill tumor cells and shrink tumors. It is not yet known whether giving hypofractionated radiation therapy or conventional radiation therapy after surgery may work better in treating patients with prostate cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. To demonstrate that hypofractionated post-prostatectomy radiotherapy (HYPORT) does not increase patient-reported gastrointestinal (GI) or genitourinary (GU) symptoms over conventionally fractionated post-prostatectomy (COPORT) at the 2-year time point.

SECONDARY OBJECTIVES:

I. To compare patient-reported GI symptoms using the Expanded Prostate Cancer Index Composite (EPIC)-26 at end of radiation therapy (RT) and 6, 12, 24, and 60 months from end of treatment.

II. To compare patient-reported GU symptoms using the EPIC-26 at end of RT and 6, 12, 24, and 60 months from end of treatment.

III. To compare the cost effectiveness based on the cost of radiotherapy and measured utilities for health outcomes using the EuroQol five dimensions questionnaire (EQ-5D).

IV. To compare time to progression (TTP) where progression is defined as the first occurrence of biochemical failure (BF), local failure, regional failure, distant metastasis (DM), institution of new unplanned anticancer treatment, or death from prostate cancer (prostate cancer specific mortality [PCSM]).

V. To compare freedom from biochemical failure (FFBF) and TTP rates with an alternate prostate specific antigen (PSA) >= PSA nadir + 2 ng/mL definition of BF.

VI. To compare local failure, regional failure, salvage therapy (i.e. institution of new unplanned anticancer treatment), DM, PCSM, and overall survival (OS) rates.

VII. Assessment of adverse events. VIII. Paraffin-embedded tissue block, serum, plasma, whole blood, and urine for future translational research analyses for predictors of toxicity following hypofractionated or conventionally fractionated post-prostatectomy radiotherapy.

After completion of study treatment, patients are followed up every 6 months for 2 years and every year for 3 years and thereafter.

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Prostate Adenocarcinoma
• Stage I Prostate Adenocarcinoma
• Stage II Prostate Adenocarcinoma
• Stage III Prostate Adenocarcinoma

Intervention

• Radiation: Hypofractionated radiation therapy
  66.6 Gy in 37 daily fractions of 1.8 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
  Other Names:

  • Hypofractionated Radiotherapy
  • hypofractionation
• Radiation: Conventional radiation therapy
  62.5 Gy in 25 daily fractions of 2.5 Gy to the prostate bed in the absence of disease progression or unacceptable toxicity.
• Drug: Optional androgen deprivation therapy
  Any luteinizing hormone-releasing hormone (LHRH) agonist/antagonist with or without an oral antiandrogen can be used up to a six-month administration dose, starting 7-9 weeks before radiation therapy and may begin as early as 42 days prior to or any time after screening. An oral antiandrogen alone is not allowed.
  Other Name: ADT

Study Arms

• Active Comparator: Conventional radiation therapy
  Conventional post-prostatectomy radiation therapy (COPORT) over 7 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
  Interventions:

  • Radiation: Conventional radiation therapy
  • Drug: Optional androgen deprivation therapy
• Experimental: Hypofractionated radiation therapy
  Hypofractionated post-prostatectomy radiation therapy (HYPORT) over 5 weeks. Patients may also receive optional androgen deprivation therapy per doctor recommendation.
  Interventions:

  • Radiation: Hypofractionated radiation therapy
  • Drug: Optional androgen deprivation therapy

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: May 10, 2022): 296
• Original Estimated Enrollment (submitted: September 5, 2017): 282
• Estimated Study Completion Date: November 2026
• Actual Primary Completion Date: December 1, 2020 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• PRIOR TO STEP 1 REGISTRATION

• Adenocarcinoma of the prostate treated primarily with radical prostatectomy

  • Any type of radical prostatectomy will be permitted, including retropubic, perineal, laparoscopic, or robotically assisted; there is no time limit for the date of radical prostatectomy

• One of the following pathologic T-classifications: pT2 or pT3

  • Patients with positive surgical margins are eligible

• One of the following pathologic N-classifications: pN0, pNX

  • If a lymph node dissection is performed, the number of lymph nodes removed per side of the pelvis and the extent of the pelvic lymph node dissection (obturator versus (vs.) extended lymph node dissection) should be noted whenever possible

• No clinical evidence of regional lymph node metastasis

  • Computed tomography (CT) (with contrast if renal function is acceptable; a noncontrast CT is permitted if the patient is not a candidate for contrast), magnetic resonance imaging (MRI), nodal sampling, or dissection of the pelvis within 120 days prior to step 1 registration
  • Patients with pelvic lymph nodes equivocal or questionable by imaging are eligible if the nodes are =< 1 cm in the short axis
• A post-radical prostatectomy study entry PSA >= 45 days after prostatectomy and within 30 days prior to step 1, < 2.0 ng/mL

• No evidence of a local recurrence in the prostate fossa based on a digital rectal examination (DRE) within 60 days prior to step 1 registration

  • Patients with equivocal or questionable DRE findings should have an MRI of the pelvis to exclude the presence of a prostate fossa mass
  • Patients with equivocal or questionable exam findings by DRE or MRI are eligible if a biopsy of the lesion is negative for tumor

• No evidence of bone metastases (M0) on bone scan (Na F positron emission tomography (PET)/CT is an acceptable substitute) within 120 days prior to step 1 registration

  • Equivocal bone scan findings are allowed if plain films and/or MRI are negative for metastasis
• Zubrod performance status 0-1 within 60 days prior to step 1 registration
• The patient or a legally authorized representative must provide study-specific informed consent prior to step 1 registration
• Willingness and ability to complete the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire
• Only English and French-speaking patients are eligible to participate
• PRIOR TO STEP 2 REGISTRATION
• The EPIC-26 must be completed in full and entered within 10 business days after step 1 registration; NRG Oncology Statistical and Data Management Center has 3 business days to score the results and send a notification to the site to proceed to step 2 randomization

Exclusion Criteria:

• A post-prostatectomy PSA nadir >= 0.2 ng/mL AND Gleason >= 7
• pT2 with a negative surgical margin and PSA < 0.1 ng/mL

• Androgen deprivation therapy started prior to prostatectomy for > 6 months (180 days) duration;

  • Note: The use of finasteride or dutasteride (? tamsulosin) for longer periods prior to prostatectomy is acceptable
• Androgen deprivation therapy started after prostatectomy and prior to step 1 registration for > 6 weeks (42 days)
• Neoadjuvant chemotherapy before or after prostatectomy
• Prior invasive (except non-melanoma skin cancer) malignancy unless disease-free for a minimum of 3 years and not in the pelvis; (for example, carcinoma in situ of the oral cavity is permissible if disease free for a minimum of 3 years; however, patients with prior history of bladder cancer are not allowed no matter the disease free duration); prior hematological (e.g., leukemia, lymphoma, myeloma) malignancy is not allowed
• Previous chemotherapy for any other disease site if given within 3 years prior to step 1
• Prior radiotherapy, including brachytherapy, to the region of the study cancer that would result in overlap of radiation therapy treatment volumes

• Severe, active co-morbidity, defined as follows:

  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
  • Transmural myocardial infarction within the last 6 months
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step 1 registration
  • Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step 1 registration
  • Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease
  • Human immunodeficiency virus (HIV) positive with CD4 count < 200 cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD4 count >= 200 cells/microliter within 30 days prior to registration; note also that HIV testing is not required for eligibility for this protocol
  • End-stage renal disease (ie, on dialysis or dialysis has been recommended)
• Prior allergic reaction to the study drugs involved in this protocol
• History of inflammatory bowel disease, prior bowel surgeries (or colostomy) for any reason, or prior partial/radical cystectomy for any reason

Sex/Gender

• Sexes Eligible for Study: Male

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: Canada, Switzerland, United States

Administrative Information

• NCT Number: NCT03274687
• Other Study ID Numbers: NRG-GU003; NCI-2016-01771 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) ); NRG-GU003; NRG-GU003 ( Other Identifier: NRG Oncology ); NRG-GU003 ( Other Identifier: CTEP ); U10CA180868 ( U.S. NIH Grant/Contract )
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

• IPD Sharing Statement: Not Provided
• Current Responsible Party: NRG Oncology
• Original Responsible Party: Same as current
• Current Study Sponsor: NRG Oncology
• Original Study Sponsor: Same as current
• Collaborators: National Cancer Institute (NCI)

Investigators

• Principal Investigator: Mark Buyyounouski; NRG Oncology

• PRS Account: NRG Oncology
• Verification Date: May 2022